Autres langues Mezzion Pharma Co.,Ltd.

Actions

A140410

KR7140410002

Cours en clôture Korea S.E. Autres places de cotation 00:00:00 13/05/2024			Varia. 5j.	Varia. 1 janv.
37 200 ^KRW	-0,80 %		-3,00 %	-4,62 %

18/03	Mezzion Pharma Co. publie ses résultats pour l'exercice clos le 31 décembre 2023	CI
2023	Mezzion Pharma Co. publie ses résultats pour le troisième trimestre et les neuf mois clos le 30 septembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Mezzion Pharma Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Mezzion Pharma Co.,Ltd. announced that it has received KRW 49.99999719 billion in funding from BRV Capital Management and other investors	20/06/23
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
Mezzion Pharma to Raise 50 Billion Won From Share Sale	20/04/23
Mezzion Pharma Co.,Ltd. announced that it expects to receive KRW 49.99999719 billion in funding from BRV Capital Management	19/04/23
Mezzion Pharma Co.,Ltd. Submits Protocol for Confirmatory Pivotal Phase 3 Trial ("FUEL-2") in Fontan Subjects	21/02/23
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/11/22
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/08/22
Mezzion Pharma Co.,Ltd. Receives Clear FDA Path Forward for the Approval of Udenafil for Single Ventricle Heart Disease	31/05/22
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	11/05/22
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	23/03/22
Mezzion Pharma Announces Positive Data Presented to FDA in Type C Meeting	21/12/21
Mezzion Pharma Co.,Ltd. announced that it has received KRW 20 billion in funding	16/11/21
Mezzion Pharma Co.,Ltd. announced that it expects to receive KRW 20 billion in funding	12/11/21
Mezzion Appoints William Breitenbach as Chief Commercial Officer for Mezzion's Global Commercial Operations	15/06/21
Mezzion's New Drug Application for Its Orphan Drug Udenafil for the Treatment of Single Ventricle Heart Disease Has Been Accepted for Filing by the FDA	26/05/21
Mezzion Pharma Co. Ltd. Announces Re-Submission of New Drug Application for its Orphan Drug Udenafil	29/03/21
Mezzion Pharma Co. Ltd. Announces Submission of New Drug Application for its Orphan Drug Udenafil to Treat Patients	30/06/20
Mezzion Pharma's Announces Results from the Pivotal 400-Subject Phase 3 Fuel Trial	18/05/20

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Mezzion Pharma Co.,Ltd.

Actions

A140410

KR7140410002

Autres langues

Filtres